Effect of Food on Pharmacokinetics of an Inhaled Drug: A Case Study with a VLA‐4 Antagonist, HMR1031

@article{Shah2003EffectOF,
  title={Effect of Food on Pharmacokinetics of an Inhaled Drug: A Case Study with a VLA‐4 Antagonist, HMR1031},
  author={Bharti Shah and Bradford K. Jensen and Jie Zhang and Thomas L. Hunt and Shashank Rohatagi},
  journal={The Journal of Clinical Pharmacology},
  year={2003},
  volume={43}
}
HMR1031 is a potent and specific antagonist of the integrin VLA‐4 (α4β1) binding to vascular cell adhesion molecule‐1 (VCAM‐1) and fibronectin. HMR1031 is an inhaled drug being developed for the treatment of asthma using an Ultrahaler® dry‐powder inhalation device. A pharmacoscintigraphic study of HMR1031 suggests a lung deposition of ∼25% and gastrointestinal tract deposition of ∼75%. Since oral absorption may be contributing to systemic plasma concentrations, the effect of food on HMR1031 was… 
Does Food Affect the Pharmacokinetics of Non-orally Delivered Drugs? A Review of Currently Available Evidence.
  • Peng Zou
  • Medicine, Biology
    The AAPS journal
  • 2022
TLDR
Clinical food effect data for non-orally administered drugs show that food intake can increase the absorption of SC and ID administered peptides and proteins with MW < 30 kDa by 30-50%.
Drivers of absolute systemic bioavailability after oral pulmonary inhalation in humans.
A Review of Food–Drug Interactions on Oral Drug Absorption
TLDR
The effects of high-fat food or standard meals on the oral drug absorption rate and absorption extent for 229 drugs based on the Biopharmaceutics Drug Disposition Classification System class and food effect are analyzed.
Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs
TLDR
Preliminary results suggest that pulmonary deposition, dissolution, and absorption are highly complex processes and may represent the major challenge for modeling and simulation of PK after oral drug inhalation.
Role of Integrin Alpha4 in Drug Resistance of Leukemia
TLDR
The available evidence supporting the targeting of alpha4 as a novel strategy for treatment of drug resistant leukemia is reviewed, with evidence of stroma-induced and alpha4-mediated nuclear factor-κB signaling in leukemia cells, disruption of which depletes leukemia cells of strong survival signals.
Effect of a very late antigen‐4 receptor antagonist on allergen‐induced airway responses and inflammation in asthma
  • Z. Diamant, J. Kuperus, J. Prins
  • Medicine
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
  • 2005
TLDR
This data indicates that VLA4 plays a key role in the recruitment of eosinophils in allergic responses in animal studies and may have an important role in protecting against fungal infections.
CBP501 suppresses macrophage induced cancer stem cell like features and metastases.
TLDR
It is demonstrated that CBP501 suppresses lipopolysaccharide (LPS)-induced production of IL-6, IL-10 and TNF-α by macrophages, and in vivo suppressed metastases of a tumor cell line, 4T1, one which is insensitive to combination treatment of CBP 501 and CDDP in vitro.
CBP501 suppresses macrophage induced cancer stem cell like features and metastases
TLDR
It is demonstrated that CBP501 suppresses lipopolysaccharide (LPS)-induced production of IL-6, IL-10 and TNF-α by macrophages, and in vivo suppressed metastases of a tumor cell line, 4T1, one which is insensitive to combination treatment of CBP 501 and CDDP in vitro.
Roles of integrin activation in eosinophil function and the eosinophilic inflammation of asthma
TLDR
This work elaborate on how integrins cooperate to mediate eosinophil movement to the asthmatic airway in a sequential, multistep paradigm.

References

SHOWING 1-10 OF 12 REFERENCES
Pharmacoscintigraphic Comparison of HMR 1031, a VLA-4 Antagonist, in Healthy Volunteers Following Delivery Via a Nebulizer and a Dry Powder Inhaler
TLDR
The lung deposition of HMR 1031 after administration by Ultrahaler was approximately 37% higher compared with the lung deposition from the nebulizer, in agreement with the relative difference in the plasma AUC values achieved after administration of the two formulations.
Clinical Pharmacokinetics of Inhaled Budesonide
TLDR
There is evidence from a population analysis that the pulmonary absorption of budesonide is prolonged and shows wide interindividual variation, and further pharmacokinetic studies are required to define the time-course of budsonide absorption through the lung in specific patient groups.
Pharmacokinetics of Triamcinolone Acetonide After Intravenous, Oral, and Inhaled Administration
TLDR
The pharmacokinetics of triamcinolone acetonide were studied after intravenous, oral (5 mg), and inhaled (2 mg) administration, causing a significant decrease in the number of lymphocytes in blood.
Clinical Pharmacokinetics of Nisoldipine Coat-Core
  • R. Heinig
  • Medicine, Biology
    Clinical pharmacokinetics
  • 1998
TLDR
Nisoldipine CC is a high-clearance drug with substantial interindividual and relatively lower intraindividual variability in pharmacokinetics, dependent on liver blood flow, which causes reductions in blood pressure which are maintained over 24 hours in the absence of releva effects on heart rate.
The influence of reduced liver blood flow on the pharmacokinetics and pharmacodynamics of recombinant tissue factor pathway inhibitor
TLDR
The aim of this study was to examine the effect of exercise‐induced reduction in liver blood flow on the pharmacokinetics and pharmacodynamics of rTFPI.
Assessment of hepatic blood flow using continuous infusion of high clearance drugs.
TLDR
Translation of concentration profiles into clearance profiles is possible making continuous assessment of hepatic blood flow feasible, and three distinct methods are described for the translation of concentration into flow.
VCAM-1/alpha 4-integrin adhesion pathway: therapeutic target for allergic inflammatory disorders.
  • C. A. Foster
  • Biology
    The Journal of allergy and clinical immunology
  • 1996
TLDR
This review summarizes some of the strategies that are currently used to selectively inhibit the VCAM-1/alpha 4 integrin pathway, including solubleVCAM-Ig fusion protein, peptide antagonists, antisense oligonucleotides, natural products, and neutralizing antibodies to VCam-1 or alpha 4integrin.
Mucosal inflammation in asthma.
TLDR
It is not possible to relate precisely the findings obtained by bronchoscopy to the clinical presentation and progression of asthma, but direct evidence obtained from allergen challenge leading to increased bronchial hyperresponsiveness during LAR, and direct evidence of inflammatory cells and their mediators in the airway mucosa and lumen after allergenic challenge argue for an active role of cells in bringing about inflammatory changes.
Clinical pharmacokinetics : concepts and applications
The Third Edition of Clinical Pharmacokinetics features considerations of both stereochemistry and the increasing number of polypeptide and protein drugs being developed; the range and number of
...
...